Evidence map›Paper›PMID 41614206›Full record

ReviewMedComm2026

Natural Products in Cancer Prevention and Therapy: Current Challenges and Future Directions.

Ruimiao Qian, Jun Ge, Ni Fan, Zheng Sun, Chengcheng Zhao, Yujiao Sun, Yingpeng Li, Yunfei Li, Hui Fu

Abstract readReview
In one paragraph

Review in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Multitarget Antiproliferative Activity ofMolecules (Basel, Switzerland) · 2026
    Article
  3. Review
  4. Review
  5. Cardiac Modulation byCurrent issues in molecular biology · 2026
    Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ruimiao QianCollege of Chinese Materia Medica Tianjin University of Traditional Chinese Medicine Tianjin China.
Jun GeCollege of Chinese Materia Medica Tianjin University of Traditional Chinese Medicine Tianjin China.
Ni FanCollege of Chinese Materia Medica Tianjin University of Traditional Chinese Medicine Tianjin China.
Zheng SunCollege of Chinese Materia Medica Tianjin University of Traditional Chinese Medicine Tianjin China.
Chengcheng ZhaoExperimental Teaching and Practical Training Center Heilongjiang University of Chinese Medicine Harbin China.
Yujiao SunCollege of Chinese Materia Medica Tianjin University of Traditional Chinese Medicine Tianjin China.
Yingpeng LiCollege of Chinese Materia Medica Tianjin University of Traditional Chinese Medicine Tianjin China.ORCID https://orcid.org/0000-0002-5043-1306
Yunfei LiCollege of Chinese Materia Medica Tianjin University of Traditional Chinese Medicine Tianjin China.
Hui FuCollege of Integrated Chinese and Western Medicine Tianjin University of Traditional Chinese Medicine Tianjin China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural products, originating from diverse biological sources, serve as a critical reservoir of bioactive compounds for cancer intervention across prevention, treatment, and supportive care. Their mechanisms extend beyond direct cytotoxicity to include modulation of tumor metabolism-such as glucose, lipid, and glutamine pathways-and the tumor microenvironment (TME), highlighting their multifaceted role in oncology. However, a systematic synthesis of how natural products concurrently target metabolic reprogramming and immune-stromal components across different clinical phases remains lacking. This review delineates the therapeutic applications of natural products-such as flavonoids, alkaloids, and terpenoids-across the clinical continuum, including perioperative support, concurrent chemoradiotherapy, maintenance therapy, and metastasis suppression. We detail their actions in disrupting core metabolic pathways and elucidate their influence on TME components like cancer-associated fibroblasts, extracellular matrix, and immune cells including tumor-associated macrophages and T lymphocytes. Furthermore, we discuss innovative delivery strategies-including nanocarriers and codelivery systems-that enhance bioavailability and enable synergistic combination with chemotherapy or immunotherapy. By integrating mechanistic insights with clinical translation strategies, this work provides a comprehensive framework for employing natural products in biomarker-driven, precision oncology regimens, supporting their evolving role in multimodal cancer care.

Indexed as

cancer metabolic reprogrammingimmune modulationnatural productsprecision medicinetumor microenvironment

Identifiers

PMID41614206
PMCPMC12848797

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.